Advancing personalized medicine for Parkinson's disease: transforming treatment and therapeutic outcomes

The emergence of personalized medicine represents a significant change in medicine and offers more accurate and personal approaches to treatment. Neurodegenerative diseases, based on progressive deterioration of the neurons, pose a considerable challenge because of their multifactorial etiological and heterogeneous clinical phenotypes. The present paper dwells on one of the prevalent neurodegenerative diseases: Parkinson's Disease. Parkinson's Disease is linked to motor symptoms, which include bradykinesia, tremor, rigidity, and posture instability. Parkinson's, as a significant movement disorder, reflects the urgency of the new treatment methods. The existing interventions, like Levodopa, Catechol-O-Methyltransferase inhibitors, and surgical procedures like Deep Brain Stimulation, are used as the current interventions. Nonetheless, these therapeutics cannot work in all patients with great success, and the response of the patients to them differs greatly. This contradiction especially highlights the gap in the contemporary paradigms of treatment and the need to transition into more individualized approaches. The use of personalized medicine with Parkinson's Disease marks a shift in the historically used one-size-fits-all approach, instead shifting to a more personalized approach. Through genetic, biomarker, and phenotypic information, personalized medicine will enhance the accuracy of diagnosis, disease progression forecasting, and treatment regimes. This literature review provides an explanation of the need for personalized medicine in Parkinson's, discusses the latest developments, techniques, limitations, and analyzes the innovative technologies and strategies. By identifying key developments and ongoing challenges, the paper aims to provide a comprehensive understanding of how personalized medicine could transform the future of Parkinson's disease management.